



18th December 2014

Company Announcements Office
Australian Securities Exchange

Nanosonics Moving to New Global Headquarters

Nanosonics (ASX:NAN), today announced it will be moving in the second half of FY15 to new global corporate and manufacturing facilities. Currently based in Alexandria, Sydney, NSW, Nanosonics will be moving to 14 Mars Road, Lane Cove, NSW, the former Global Headquarters of Cochlear Limited.

The new headquarters provide the organisation with more than double its existing space with the opportunity for further expansion in the future. Having all operations on a single site compared to the current seven unit structure in Alexandria provides great opportunities for improved efficiencies across the business. The new facility is also in an ideal location being a hub for many medical technology organisations.

"Moving to these new facilities is a core component of our strategic plan and has been on our agenda for some time. The move gives extended flexibility in manufacturing capacity and capability as well as affording the opportunity for greater operational expansion and efficiencies," said Michael Kavanagh, Nanosonics Chief Executive Officer and President. "Attractive terms were negotiated and, despite the increase in the size of the facility, the total ongoing occupancy cost will not increase materially. As the building was an established medical technology facility, capital investment is expected to be less than \$2.0 million to tailor the facilities to our specific operational requirements."

Michael Kavanagh
CEO / President

For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600
Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722
Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit www.nanosonics.com.au